Back to Search Start Over

Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms

Authors :
Julie Lucifora
Dulce Alfaiate
Caroline Pons
Maud Michelet
Ricardo Ramirez
Floriane Fusil
Fouzia Amirache
Axel Rossi
Anne-Flore Legrand
Emilie Charles
Serena Vegna
Rayan Farhat
Michel Rivoire
Guillaume Passot
Nicolas Gadot
Barbara Testoni
Charlotte Bach
Thomas F. Baumert
Anastasia Hyrina
Rudolf K. Beran
Fabien Zoulim
Andre Boonstra
Hildegard Büning
Eloi R. Verrier
François-Loïc Cosset
Simon P. Fletcher
Anna Salvetti
David Durantel
Centre International de Recherche en Infectiologie (CIRI)
École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Institut des Agents Infectieux [Lyon] (IAI)
Hospices Civils de Lyon (HCL)
Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL)
Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Gilead Sciences, Inc. [Foster City, CA, USA]
Virus enveloppés, vecteurs et immunothérapie – Enveloped viruses, Vectors and Immuno-therapy (EVIR)
Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL)
Institute of Experimental Hematology [Hannover, Germany]
Hannover Medical School [Hannover] (MHH)
Application des ultrasons à la thérapie (LabTAU)
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)
Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL]
Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS)
Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)
Centre pour l'innovation en cancérologie de Lyon (CICLY)
Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon
Centre Léon Bérard [Lyon]
Institut de Recherche sur les Maladies Virales et Hépatiques (IVH)
Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Hôpital de la Croix-Rousse [CHU - HCL]
Gastroenterology and Hepatology
Erasmus University Medical Center [Rotterdam] (Erasmus MC)
German Center for Infection Research - partner site Hannover-Braunschweig (DZIF)
Gastroenterology & Hepatology
Source :
Journal of Hepatology, Journal of Hepatology, In press, ⟨10.1016/j.jhep.2023.01.005⟩, Journal of Hepatology, 78(5), 958-970. Elsevier
Publication Year :
2023

Abstract

Background & Aims: Chronic coinfection with HBV and HDV leads to the most aggressive form of chronic viral hepatitis. Herein, we aimed to elucidate the molecular mechanisms underlying the widely reported observation that HDV interferes with HBV in most coinfected patients. Methods: Patient liver tissues, primary human hepatocytes, HepaRG cells and human liver chimeric mice were used to analyze the effect of HDV on HBV using virological and RNA-sequencing analyses, as well as RNA synthesis, stability and association assays. Results: Transcriptomic analyses in cell culture and mouse models of coinfection enabled us to define an HDV-induced signature, mainly composed of interferon (IFN)-stimulated genes (ISGs). We also provide evidence that ISGs are upregulated in chronically HDV/HBV-coinfected patients but not in cells that only express HDV antigen (HDAg). Inhibition of the hepatocyte IFN response partially rescued the levels of HBV parameters. We observed less HBV RNA synthesis upon HDV infection or HDV protein expression. Additionally, HDV infection or expression of HDAg alone specifically accelerated the decay of HBV RNA, and HDAg was associated with HBV RNAs. On the contrary, HDAg expression did not affect other viruses such as HCV or SARS-CoV-2. Conclusions: Our data indicate that HDV interferes with HBV through both IFN-dependent and IFN-independent mechanisms. Specifically, we uncover a new viral interference mechanism in which proteins of a satellite virus affect the RNA production of its helper virus. Exploiting these findings could pave the way to the development of new therapeutic strategies against HBV. Impact and implications: Although the molecular mechanisms remained unexplored, it has long been known that despite its dependency, HDV decreases HBV viremia in patients. Herein, using in vitro and in vivo models, we showed that HDV interferes with HBV through both IFN-dependent and IFN-independent mechanisms affecting HBV RNA metabolism, and we defined the HDV-induced modulation signature. The mechanisms we uncovered could pave the way for the development of new therapeutic strategies against HBV by mimicking and/or increasing the effect of HDAg on HBV RNA. Additionally, the HDV-induced modulation signature could potentially be correlated with responsiveness to IFN-α treatment, thereby helping to guide management of HBV/HDV-coinfected patients.

Details

Language :
English
ISSN :
01688278 and 16000641
Database :
OpenAIRE
Journal :
Journal of Hepatology, Journal of Hepatology, In press, ⟨10.1016/j.jhep.2023.01.005⟩, Journal of Hepatology, 78(5), 958-970. Elsevier
Accession number :
edsair.doi.dedup.....cc3b3eff3a87ef013cb5c6dbae104bda
Full Text :
https://doi.org/10.1016/j.jhep.2023.01.005⟩